Concepedia

Mark E. Labadia

ME

Statistics

Publications

19

Citations

1.9K

H-Index

17

Active since

1990

Affiliations

Boehringer Ingelheim (United States)(Current)

Boehringer Ingelheim (France)

Boehringer Ingelheim (Japan)

Mark E. Labadia is an author at Boehringer Ingelheim (United States) specializing in life sciences, immunology, and pharmacology.

Publications per year

1990–2021

19

Publications

19

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

Vincent J. Merluzzi, Karl D. Hargrave, Mark E. Labadia et al. · Science · 1990 · 746 citations

, , +17

RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients

Koen Venken, Peggy Jacques, Céline Mortier et al. · Nature Communications · 2018 · 310 citations · Full text

, , +17

High-Affinity Interactions of Tumor Necrosis Factor Receptor-Associated Factors (TRAFs) and CD40 Require TRAF Trimerization and CD40 Multimerization

Steven S. Pullen, Mark E. Labadia, Richard H. Ingraham et al. · Biochemistry · 1999 · 148 citations

, , +17

Discovery and Characterization of a Substrate Selective p38α Inhibitor

Walter Davidson, Lee Frego, Gregory W. Peet et al. · Biochemistry · 2004 · 110 citations

, , +17

Epstein‐Barr virus‐induced gene 3 negatively regulates IL‐17, IL‐22 and RORγt

Jianfei Yang, Min Yang, Tin Min Htut et al. · European Journal of Immunology · 2008 · 98 citations · Full text

, , +14

1–5 of 19